Abstract
Opioids are commonly used analgesics in clinical practice. Three opioid receptors (μ, δ and κ) that mediate opioid effects have been identified by molecular cloning. Each type of opioid receptors consists of subtypes of receptors as suggested by pharmacological studies. Although μ opioid receptors are the major receptor to mediate the analgesic effects of opioids, δ and κ receptors are also important in anti-nociception (for example, δ and κ receptors can mediate spinal analgesia). Recently, the cytoprotective effects of opioids have been recognized. The presence of opioids during harmful events such as ischemia reduces cell injury in multiple organs including heart and brain. These effects appear to be mediated by δ receptors in most studies. A new form of cytoprotection in which a prior exposure to opioids renders protection against cell ischemia (opioid preconditioning) has been identified. In the heart, this opioid preconditioning-induced protection has
Keywords: opioids, opioid receptors, analgesia, ischemia-reperfusion injury, cardioprotection, neuroprotection, preconditioning
Current Pharmaceutical Design
Title: Opioids: Old Drugs for Potential New Applications
Volume: 11 Issue: 10
Author(s): U. Barry and Z. Zuo
Affiliation:
Keywords: opioids, opioid receptors, analgesia, ischemia-reperfusion injury, cardioprotection, neuroprotection, preconditioning
Abstract: Opioids are commonly used analgesics in clinical practice. Three opioid receptors (μ, δ and κ) that mediate opioid effects have been identified by molecular cloning. Each type of opioid receptors consists of subtypes of receptors as suggested by pharmacological studies. Although μ opioid receptors are the major receptor to mediate the analgesic effects of opioids, δ and κ receptors are also important in anti-nociception (for example, δ and κ receptors can mediate spinal analgesia). Recently, the cytoprotective effects of opioids have been recognized. The presence of opioids during harmful events such as ischemia reduces cell injury in multiple organs including heart and brain. These effects appear to be mediated by δ receptors in most studies. A new form of cytoprotection in which a prior exposure to opioids renders protection against cell ischemia (opioid preconditioning) has been identified. In the heart, this opioid preconditioning-induced protection has
Export Options
About this article
Cite this article as:
Barry U. and Zuo Z., Opioids: Old Drugs for Potential New Applications, Current Pharmaceutical Design 2005; 11 (10) . https://dx.doi.org/10.2174/1381612053507459
DOI https://dx.doi.org/10.2174/1381612053507459 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Tumoricidal and Anti-Angiogenic Actions of Gamma-Linolenic Acid and Its Derivatives
Current Pharmaceutical Biotechnology Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Current Drug Targets Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Combined Ischemic Preconditioning and Resveratrol Improved Bloodbrain Barrier Breakdown <i>via</i> Hippo/YAP/TAZ Signaling Pathway
CNS & Neurological Disorders - Drug Targets Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery
Current Vascular Pharmacology A Review on Response of Immune System in Spinal Cord Injury and Therapeutic Agents useful in Treatment
Current Pharmaceutical Biotechnology Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Dipyridamole: A Drug with Unrecognized Antioxidant Activity
Current Topics in Medicinal Chemistry The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery Programmed Cell Death after Intracerebral Hemorrhage
Current Neuropharmacology Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology